(Q38150405)

29 August 2017

title

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview (English)

1 reference

29 August 2017

0 references

Benjamin M. Greenberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

P S Rommer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

U K Zettl

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

B Kieseier

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

H-P Hartung

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

T Menge

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

E Frohman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

B Hemmer

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

O Stüve

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 March 2014

1 reference

Clinical and Experimental Immunology

29 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

397-407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24102425%20AND%20SRC:MED&resulttype=core&format=json

Defining the clinical course of multiple sclerosis: Results of an international survey

1 June 2020

cites work

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927900

21 January 2018

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

1 October 2018

1 reference

Multiple sclerosis treatment and infectious issues: update 2013.

21 January 2018

1 reference

Glatiramer acetate for multiple sclerosis

21 January 2018

1 reference

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

21 January 2018

1 reference

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 January 2018

1 reference

Glatiramer acetate in multiple sclerosis: a review.

21 January 2018

1 reference

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo

21 January 2018

1 reference

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

21 January 2018

1 reference

Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis

21 January 2018

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

Glatiramer acetate induced hepatotoxicity.

21 January 2018

1 reference

Interferon-beta mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

21 January 2018

1 reference

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

Lethal capillary leak syndrome after a single administration of interferon beta-1b.

21 January 2018

1 reference

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

Therapeutic role of mitoxantrone in multiple sclerosis

21 January 2018

1 reference

Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis

21 January 2018

1 reference

Severe heart failure in a young multiple sclerosis patient

21 January 2018

1 reference

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

21 January 2018

1 reference

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

21 January 2018

1 reference

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review

21 January 2018

1 reference

Natalizumab: targeting alpha4-integrins in multiple sclerosis

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients

21 January 2018

1 reference

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

JC virus antibody status underestimates infection rates

21 January 2018

1 reference

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

21 January 2018

1 reference

Melanoma complicating treatment with natalizumab for multiple sclerosis

21 January 2018

1 reference

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

21 January 2018

1 reference

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Vaccination against infection in patients with multiple sclerosis

21 January 2018

1 reference

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

Alemtuzumab and multiple sclerosis: therapeutic application

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

Current and emerging multiple sclerosis therapeutics

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927900

Monoclonal antibodies and progressive multifocal leukoencephalopathy.

1 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927900

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927900

Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study

1 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927900

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

1 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3927900

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 October 2018

1 reference

PML in a patient treated with fumaric acid

21 January 2018

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference

1 reference

12 December 2020

Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration

1 reference

12 December 2020

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab

1 reference

12 December 2020

Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis

1 reference

12 December 2020

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

12 December 2020

The natural history of multiple sclerosis: update 1998

1 reference

12 December 2020

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

1 reference

12 December 2020

[Treatment of psoriasis vulgaris.]

1 reference

12 December 2020

[Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate]

1 reference

12 December 2020

Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis

1 reference

12 December 2020

Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Manufacturer's response to case reports of PML

1 reference

12 December 2020